TenSixteen Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TenSixteen Bio, Inc. - overview
Established
2020
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2020, TenSixteen Bio, Inc. operates as a biotechnology company focused on developing novel therapeutics for a variety of diseases using somatic mosaicism and clonal hematopoiesis (CHIP) technique. The company was co-founded by CEO Mark Chao, physician-scientist and former co-founder of Forty Seven, an immuno-oncology company, and Pradeep Natarajan. In January 2022, TenSixteen Bio, Inc.
raised USD 30 million in Series A funding co-led by new investors Foresite Capital and GV. The Series A funding values TenSixteen Bio, Inc at 66. 1 million post-money. TenSixteen Bio is building a comprehensive multi-omics and clinical data platform on CHIP (clonal hematopoiesis of indeterminate potential) coupled with a proprietary diagnostic assay on CHIP, the platform will enable the company to discover therapeutic targets of CHIP, identify which patients are at the highest risk, and bring tailored therapies to these patients in the form of a biomarker.
The company plans to use the funding for leveraging CHIP testing and create new therapeutics that may help treat disease.
Current Investors
GV, Foresite Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.tensixteen.bio
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.